Sandbox: differentialdx maria: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
{| | {| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align=center | ||
! colspan="2" style="text-align: center;" | | |valign=top| | ||
|+ | |||
!style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center; colspan="2" style="text-align: center;"| | |||
'''Mucoepidermoid carcinoma staging''' <br><SMALL>Adapted from American Joint Committee on Cancer (AJCC). 1998 <ref name="AJCC">AJCC System for Staging of Benign and Malignant Salivary Gland Tumors. AJCC Accessed on February 18, 2016 </ref></SMALL> | '''Mucoepidermoid carcinoma staging''' <br><SMALL>Adapted from American Joint Committee on Cancer (AJCC). 1998 <ref name="AJCC">AJCC System for Staging of Benign and Malignant Salivary Gland Tumors. AJCC Accessed on February 18, 2016 </ref></SMALL> | ||
|- | |- | ||
| rowspan="5" | Tumor | |style="padding: 0 5px; background: #DCDCDC" rowspan="5" |{{fontcolor|#000| '''Tumor'''}} | ||
| | |style="padding: 5px 5px; background: #F5F5F5;"| | ||
*T1 - 2cm or less w/o extraparenchymal extension | *T1 - 2cm or less w/o extraparenchymal extension | ||
|- | |- | ||
| | |style="padding: 5px 5px; background: #F5F5F5;"| | ||
*T2 - >2cm but not greater than 4cm; and w/o extraparenchymal extension | *T2 - >2cm but not greater than 4cm; and w/o extraparenchymal extension | ||
|- | |- | ||
| | |style="padding: 5px 5px; background: #F5F5F5;"| | ||
*T3 - >4cm or with extraparenchymal extension | *T3 - >4cm or with extraparenchymal extension | ||
|- | |- | ||
| | |style="padding: 5px 5px; background: #F5F5F5;"| | ||
*T4a - invades skin,mandible, ear canal or facial nerve | *T4a - invades skin,mandible, ear canal or facial nerve | ||
|- | |- | ||
| | |style="padding: 5px 5px; background: #F5F5F5;"| | ||
*T4b - invades skull base, pterygoid plates or encases carotid | *T4b - invades skull base, pterygoid plates or encases carotid | ||
|- | |- | ||
| rowspan="5" | Nodes | |style="padding: 0 5px; background: #DCDCDC" rowspan="5" |{{fontcolor|#000| '''Nodes'''}} | ||
| | |style="padding: 5px 5px; background: #F5F5F5;"| | ||
*NX - Cannot be assessed | *NX - Cannot be assessed | ||
|- | |- | ||
| | | style="padding: 5px 5px; background: #F5F5F5;"| | ||
*N0 - No regional lymph nodes metastasis | *N0 - No regional lymph nodes metastasis | ||
|- | |- | ||
| | |style="padding: 5px 5px; background: #F5F5F5;"| | ||
*N1 - Single ipsilateral lymph node, <= 3cm in greatest dimension | *N1 - Single ipsilateral lymph node, <= 3cm in greatest dimension | ||
|- | |- | ||
| | |style="padding: 5px 5px; background: #F5F5F5;"| | ||
*N2 | *N2 | ||
*N2a - Single ipsilateral lymph node, 3-6 cm in greatest dimension | *N2a - Single ipsilateral lymph node, 3-6 cm in greatest dimension | ||
Line 36: | Line 38: | ||
*N2c - Bilateral or contralateral lymph nodes, <= 6cm in greatest dimension | *N2c - Bilateral or contralateral lymph nodes, <= 6cm in greatest dimension | ||
|- | |- | ||
| *N3 - Lymph node(s) >6 cm in greatest dimension | |style="padding: 5px 5px; background: #F5F5F5;"| | ||
*N3 - Lymph node(s) >6 cm in greatest dimension | |||
|- | |- | ||
| rowspan="6" | Overall stage | |style="padding: 0 5px; background: #DCDCDC" rowspan="6" |{{fontcolor|#000|'''Overall stage'''}} | ||
| | |style="padding: 5px 5px; background: #F5F5F5;"| | ||
*I - T1 N0 | *I - T1 N0 | ||
|- | |- | ||
| | |style="padding: 5px 5px; background: #F5F5F5;"| | ||
*II - T2 N0 | *II - T2 N0 | ||
|- | |- | ||
| | |style="padding: 5px 5px; background: #F5F5F5;"| | ||
*III - T3 N0-1, or T1-3 N1 | *III - T3 N0-1, or T1-3 N1 | ||
|- | |- | ||
| | |style="padding: 5px 5px; background: #F5F5F5;"| | ||
*IVA - T4a N0-2, or T1-4a | *IVA - T4a N0-2, or T1-4a | ||
|- | |- | ||
| | |style="padding: 5px 5px; background: #F5F5F5;"| | ||
*IVB - T4b N0-3, or T1-4b N3 | *IVB - T4b N0-3, or T1-4b N3 | ||
|- | |- | ||
| | |style="padding: 5px 5px; background: #F5F5F5;"| | ||
*IVC - M1 | *IVC - M1 | ||
|} | |} |
Revision as of 16:00, 19 February 2016
Mucoepidermoid carcinoma staging | |
---|---|
Tumor |
|
| |
| |
| |
| |
Nodes |
|
| |
| |
| |
| |
Overall stage |
|
| |
| |
| |
| |
|
Differential Diagnosis | Similar Features | Differentiating Features |
---|---|---|
Benign mixed tumor | Painless parotid swelling and facial deformity | In benign mixed tumor , differentiating features include: histopathological findings |
Warthin tumor | Painless swelling and facial deformity | In warthin tumor differentiating features include: multicentric presentation (20%) and are usually small (1-4 cm), highly associated with smoking |
Adenoid cystic carcinoma | Swelling on salivary gland and facial deformity | In adenoid cystic carcinoma, differentiating features include: tendency for perineural extension, distribution, and mainly occur in relation to the airways |
Metastasis | Painless swelling and facial deformity | In metastasis, differentiating features include: primary tumor origin, and histopathological findings. |
Type of tumor | Age | Location | Histological features | Imaging features | Origin | Bone/Cartilage |
---|---|---|---|---|---|---|
Osteoma | 40-50 years | Skull bones | Matured lamellar bone | Sclerotic | Benign | Bone |
Osteoid osteoma | 10-20 years | Short and long bone diaphysis | Osteiod outlined by osteoblasts, incorporated in a fibrous stroma | Sclerotic | Benign | Bone |
Osteosarcoma | 11-40 years | Long bones metaphysis | Osteoid and bone formed of malignant osteoblasts and fibroblasts | Sclerotic | Malignant | Bone |
Chondroma | 30-60 years | Small tubular bones of the hands and feet | Maturated hyaline cartilage (enchondroma/ecchondroma), preserving lobulation | Well-defined | Malignant | Cartilage |
Chondrosarcoma | 30-60 years | Long bones metaphysic, axial skeleton | Immature cartilage, no preserving lobulation, cells arranged in groups of two or four, with atypia and mitosis | Well-defined | Malignant | Cartilage |
Ewing sarcoma | 5-25 years | Long bones diaphysis | Small, round, undifferentiated cells, no stroma, a lot of capillary arrangement. | Ill-defined | Malignant | Bone |
Giant cell tumor | 20-40 years | Knee | Multinucleated giant cells, fusiform cells, mononuclear cells. | Well-defined | Malignant | Bone |
Metastases | 50-90 years | No site predilection | Frequently adenocarcinomas. Metastases can be blastic or lytic depending on the tumor origin | Sclerotic | Malignant | Bone |
Stage | Description |
---|---|
I |
|
II |
|
III |
|
Differential Diagnosis | Similar Features | Differentiating Features |
---|---|---|
Enchondroma |
|
|
Chondroblastoma |
|
|
Periosteal chondroma |
|
|
Chondromyxoid fibroma |
|
|
Type of osteochondroma | Features |
---|---|
Solitary osteochondroma |
|
Multiple osteochondromas (hereditary) |
|
Genes implicated in HNPCC | Frequency of mutations in HNPCC families | Locus |
---|---|---|
MSH2 | approximately 60% | 2p22 |
MLH1 | approximately 30% | 3p21 |
MSH6 | 7-10% | 2p16 |
PMS2 | relatively infrequent | 7p22 |
PMS1 | case report | 2q31-q33 |
TGFBR2 | case report | 3p22 |
MLH3 | disputed | 14q24.3 |
Type of osteoid osteoma | Characteristics |
---|---|
Intracortical | Dense sclerosis around the nidus |
Periosteal | Periosteal reaction |
Cancellous (medullary) | Produces very little reactive bone |
Subarticular | Simulates arthritis as it produces synovial reactions |
Differential Diagnosis | Similar Features | Differentiating Features |
---|---|---|
Osteoblastoma |
|
|
Brodie abscess |
|
|
Osteosarcoma |
|
|
Enostosis |
|
|
Differential Diagnosis | Similar Features | Differentiating Features |
---|---|---|
Fibrous dysplasia |
|
|
Osteoblastoma |
|
|
Adamantinomas |
|
|
Chronic sinusitis |
|
|
Differential Diagnosis | Similar Features | Differentiating Features |
---|---|---|
Cardiac tamponade |
|
|
Chronic obstructive pulmonary disease |
|
|
Mediastinitis |
|
|
Pneumonia |
|
|
Acute respiratory distress syndrome |
|
|
Syphilis |
|
|
Differential Diagnosis | Similar Features | Differentiating Features |
---|---|---|
Familial adenomatous polyposis (FAP) |
|
|
Juvenile polyposis |
|
|
Cowden syndrome |
|
|
- ↑ AJCC System for Staging of Benign and Malignant Salivary Gland Tumors. AJCC Accessed on February 18, 2016